- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04742569
Wearable Diagnostic for Detection of COVID-19 Infection
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is an open label iterative study designed to calibrate the algorithm to maximize its test characteristics. The sample size is derived from the minimum number of COVID-19 subjects required to evaluate algorithm sensitivity and specificity. A sample size of 200 true positive COVID-19 infections is anticipated to assess device predictive analytics. Assuming a six-month enrollment period, a 15 percent patient lost to follow-up rate, and a positive COVID-19 infection rate of 10 percent within the study population, a sample size of 2,352 subjects will be enrolled in this prospective study.
Primary Outcomes: The primary outcomes of interest are performance of the BioSticker multiparameter vital signs wearable and the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19 related signs and symptom in subjects prior to or coincident with a positive COVID-19 diagnostic test and the specificity of the BioSticker algorithms in distinguishing positive diagnosis of infection from negative diagnosis of infection among subjects. COVID-19 infection will be confirmed by both participant affirmation and diagnostic laboratory testing. Additional primary outcome is the intuitive presentation of affirmative diagnostic results from the BioSticker early detection algorithm(s).
Secondary Outcomes: The secondary outcomes of interest include correlation of biometric data indicators to individual-level experiential feedback reported through participant symptom-tracking and diagnostic questionnaires.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Colorado
-
Greenwood Village, Colorado, États-Unis, 80111
- ClinOne, Inc
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Cohort 1- Exposed/Early Symptomatic Group All adult subjects seeking a COVID-19 test and meeting enrollment criteria will be offered enrollment into this study.
The Inclusion Criteria are:
- Adults - 18 years of age and older
- Both genders, all races and ethnic groups
- English speaking adult subjects only
Cohort 2- Vaccine Group:
Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine
- Subjects who are scheduled to receive the COVID vaccination series through local and national clinics, health systems and pharmacies.
- Subjects who become aware of the study through public notices, postings, and advertisements, and other marketing efforts.
La description
Cohort 1- Exposed/ Early Symptomatic Group
Inclusion Criteria:
- age 18 or older;
- able to follow the study device wear instructions per the Instructions for Use;
- no positive viral test within 60 days prior to enrollment; and
- willing and able to provide written, informed consent.
Exclusion Criteria:
- pregnant or breastfeeding;
- wearing a defibrillator or pacemaker;
- known or suspected cardiac dysrhythmias
- known or suspected allergy to adhesives;
- chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
- open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
- current or planned use of either an investigation pharmaceutical or an investigational device during the study.
Cohort 1- Vaccine Group
Inclusion Criteria:
Subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series are eligible for the study if they are:
- Age 18 or older; 12 years of age -17 years of age are approved to participate in the vaccine Cohort portion of the study.
- scheduled to receive their first and second dose of the Pfizer/BioNTech or Moderna COVID-19 vaccine
- able to follow the study device wear instructions per the Instructions for Use;
- no positive viral test within 60 days prior to enrollment; and
- willing and able to provide written, informed consent.
- Willing and able to take an oral temperature
Exclusion Criteria:
Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series will be excluded from the study if they are or have any of the following:
- pregnant or breastfeeding;
- wearing a defibrillator or pacemaker;
- known or suspected cardiac dysrhythmias
- known or suspected allergy to adhesives;
- chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
- open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
- current or planned use of either an investigation pharmaceutical or an investigational device during the study.
- previously fully vaccinated subjects
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
---|
Cohort 1- Exposed/Early Symptomatic
The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing. For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day. |
CoHort 2- Pfizer or Moderna Vaccine
Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series.
For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.
Délai: 14 days
|
Biometric data will be measured for 14 days using the application of the BioSticker on the upper left side of the chest.
|
14 days
|
The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.
Délai: 14 days
|
Vital Signs measurements will be collected for 14 days using the application of the BioSticker on the upper left side of the chest.
|
14 days
|
The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.
Délai: 14 days
|
Symptom tracking data will be collected through daily questionnaires for 14 consecutive days, administered through ClinOne.
Health data known to be associated with COVID-19 risk and severity, including comorbid conditions, risk factors, and demographic data will be collected from subjects during screening and enrollment via the ClinOne study website.
|
14 days
|
The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.
Délai: 14 days
|
BioSticker sensor data will be time-stamped and annotated against clinical events (e.g., fever, cough), symptom progression data, and other indicators of infection as they are identified.
Weighting coefficients for predictive algorithms will be tuned and algorithms will be iteratively refined using machine learning methods and small batches of data anticipated to include between 20 and 50 positive cases per set, and validated against sensor data obtained from COVID-19-negative subjects.
|
14 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.
Délai: 14 days
|
Individual-level experiential feedback will be reported through participant symptom- tracking and diagnostic questionnaires for 14 consecutive days.
|
14 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: James Mault, MD, BioIntelliSense, Inc
Publications et liens utiles
Publications générales
- Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020 Aug 18;173(4):262-267. doi: 10.7326/M20-1495. Epub 2020 May 13.
- Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Salanti G, Low N. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020 Sep 22;17(9):e1003346. doi: 10.1371/journal.pmed.1003346. eCollection 2020 Sep.
- Natarajan A, Su HW, Heneghan C. Assessment of physiological signs associated with COVID-19 measured using wearable devices. NPJ Digit Med. 2020 Nov 30;3(1):156. doi: 10.1038/s41746-020-00363-7.
- Ra SH, Lim JS, Kim G, et al. Thorax Epub ahead of print: 2020 September 22; doi:10.1136/ thoraxjnl-2020-215042
- Rudolph JL, Halladay CW, Barber M, McConeghy KW, Mor V, Nanda A, Gravenstein S. Temperature in Nursing Home Residents Systematically Tested for SARS-CoV-2. J Am Med Dir Assoc. 2020 Jul;21(7):895-899.e1. doi: 10.1016/j.jamda.2020.06.009. Epub 2020 Jun 9.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 1294415
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur COVID-19 [feminine]
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlComplétéSéquelles post-aiguës de la COVID-19 | État post-COVID-19 | Long-COVID | Syndrome chronique du COVID-19Italie
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkPas encore de recrutementSyndrome post-COVID-19 | Longue COVID | Longue Covid19 | État post-COVID-19 | Syndrome post-COVID | Condition post-COVID-19, non précisée | État post-COVIDPays-Bas
-
Indonesia UniversityRecrutementSyndrome post-COVID-19 | Longue COVID | État post-COVID-19 | Syndrome post-COVID | Longue COVID-19Indonésie
-
Yang I. PachankisActif, ne recrute pasInfection respiratoire COVID-19 | Syndrome de stress COVID-19 | Effet indésirable du vaccin COVID-19 | Thromboembolie associée au COVID-19 | Syndrome de soins post-intensifs COVID-19 | AVC associé à la COVID-19Chine
-
Massachusetts General HospitalRecrutementSyndrome post-aigu COVID-19 | Longue COVID | Séquelles post-aiguës de la COVID-19 | Longue COVID-19États-Unis
-
Sheba Medical CenterInconnue
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin No.2 Hospital et autres collaborateursRecrutementCOVID-19 [feminine] | Syndrome post-COVID-19 | COVID-19 post-aiguë | COVID-19 aiguëChine
-
Jonathann Kuo, MDActif, ne recrute pasInfection par le SRAS-CoV2 | Syndrome post-COVID-19 | Dysautonomie | Syndrome post-aigu COVID-19 | Longue COVID | Longue Covid19 | COVID-19 récurrent | COVID-19 post-aiguë | Infection COVID-19 post-aiguë | Séquelles post-aiguës de la COVID-19 | Dysautonomie comme trouble | Dysautonomie Syndrome d'hypotension... et d'autres conditionsÉtats-Unis
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecrutementCOVID-19 Pneumonie | Infection respiratoire COVID-19 | Pandémie de covid-19 | COVID-19 Syndrome de Détresse Respiratoire Aiguë | COVID-19-Pneumonie associée | Coagulopathie associée au COVID 19 | COVID-19 (maladie à coronavirus 2019) | Thromboembolie associée au COVID-19Grèce
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecrutementPandémie de covid-19 | Vaccins contre le covid-19 | Maladie à virus COVID-19Indonésie